Aethlon Medical (NASDAQ:AEMD) Share Price Crosses Below 200-Day Moving Average – What’s Next?

Shares of Aethlon Medical, Inc. (NASDAQ:AEMD) crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $6.87 and traded as low as $5.82. Aethlon Medical shares last traded at $5.86, with a volume of 44,949 shares traded.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. HC Wainwright restated a “neutral” rating on shares of Aethlon Medical in a research note on Friday, September 18th. Wall Street Zen raised shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a research note on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Aethlon Medical currently has a consensus rating of “Reduce” and an average price target of $1.50.

Aethlon Medical Stock Down 9.5%

The stock has a market capitalization of $3.59 million, a PE ratio of -0.14 and a beta of 1.21. The firm has a 50 day moving average price of $3.86 and a 200-day moving average price of $6.82.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) EPS for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10). Equities analysts expect that Aethlon Medical, Inc. will post -5.74 earnings per share for the current fiscal year.

Aethlon Medical Company Profile

Aethlon Medical, Inc is a medical technology company focused on developing extracorporeal filtration systems designed to remove harmful biological materials from the blood. The company’s primary technology is the Hemopurifier, an investigational device intended to capture disease-related particles, including exosomes and certain viruses, during blood filtration.

The Hemopurifier is being studied for potential applications in oncology and infectious disease. In cancer research, the device is designed to remove tumor-derived exosomes, which may contribute to immune suppression and disease progression.